Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy by Hoyoung M. Maeng, Brittni N. Moore, Hadi Bagheri, Seth M. Steinberg, Jon Inglefield, Kim Dunham, Wei-Zen Wei, John C. Morris, Masaki Terabe, Lee C. England, Brenda Roberson, Douglas Rosing, Vandana Sachdev, Svetlana D. Pack, Markku M. Miettinen, Frederic G. Barr, Louis M. Weiner, Sandhya Panch, David F. Stroncek, Lauren V. Wood, Jay A. Berzofsky

Get full text

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability by Elizabeth K. Graydon, Elizabeth K. Graydon, Tonia L. Conner, Kim Dunham, Cara Olsen, Emilie Goguet, Emilie Goguet, Si’Ana A. Coggins, Si’Ana A. Coggins, Marana Rekedal, Marana Rekedal, Emily Samuels, Emily Samuels, Belinda Jackson-Thompson, Belinda Jackson-Thompson, Matthew Moser, Matthew Moser, Alyssa Lindrose, Alyssa Lindrose, Monique Hollis-Perry, Gregory Wang, Gregory Wang, Santina Maiolatesi, Santina Maiolatesi, Yolanda Alcorta, Yolanda Alcorta, Anatalio Reyes, Anatalio Reyes, Mimi Wong, Mimi Wong, Kathy Ramsey, Kathy Ramsey, Julian Davies, Julian Davies, Edward Parmelee, Edward Parmelee, Orlando Ortega, Orlando Ortega, Mimi Sanchez, Mimi Sanchez, Sydney Moller, Jon Inglefield, David Tribble, Timothy Burgess, Robert O’Connell, Allison M. W. Malloy, Simon Pollett, Simon Pollett, Christopher C. Broder, Eric D. Laing, Stephen K. Anderson, Edward Mitre

Get full text